153 related articles for article (PubMed ID: 26988306)
1. Selective inhibitors of Bcl-2 and Bcl-xL: Balancing antitumor activity with on-target toxicity.
Hennessy EJ
Bioorg Med Chem Lett; 2016 May; 26(9):2105-14. PubMed ID: 26988306
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design of potent Bcl-2/Bcl-xL inhibitors with strong in vivo antitumor activity.
Zhou H; Aguilar A; Chen J; Bai L; Liu L; Meagher JL; Yang CY; McEachern D; Cong X; Stuckey JA; Wang S
J Med Chem; 2012 Jul; 55(13):6149-61. PubMed ID: 22747598
[TBL] [Abstract][Full Text] [Related]
3. Development of 3-phenyl-N-(2-(3-phenylureido)ethyl)-thiophene-2-sulfonamide compounds as inhibitors of antiapoptotic Bcl-2 family proteins.
Yang C; Chen S; Zhou M; Li Y; Li Y; Zhang Z; Liu Z; Ba Q; Li J; Wang H; Yan X; Ma D; Wang R
ChemMedChem; 2014 Jul; 9(7):1436-52. PubMed ID: 24782462
[TBL] [Abstract][Full Text] [Related]
4. Studies leading to potent, dual inhibitors of Bcl-2 and Bcl-xL.
Bruncko M; Oost TK; Belli BA; Ding H; Joseph MK; Kunzer A; Martineau D; McClellan WJ; Mitten M; Ng SC; Nimmer PM; Oltersdorf T; Park CM; Petros AM; Shoemaker AR; Song X; Wang X; Wendt MD; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
J Med Chem; 2007 Feb; 50(4):641-62. PubMed ID: 17256834
[TBL] [Abstract][Full Text] [Related]
5. Structure-Guided Development of Potent Benzoylurea Inhibitors of BCL-X
Roy MJ; Vom A; Okamoto T; Smith BJ; Birkinshaw RW; Yang H; Abdo H; White CA; Segal D; Huang DCS; Baell JB; Colman PM; Czabotar PE; Lessene G
J Med Chem; 2021 May; 64(9):5447-5469. PubMed ID: 33904752
[TBL] [Abstract][Full Text] [Related]
6. [Progress in small-molecule inhibitors of Bcl-2 family proteins].
Tang Y; Zhang DY; Wu XM
Yao Xue Xue Bao; 2008 Jul; 43(7):669-77. PubMed ID: 18819468
[TBL] [Abstract][Full Text] [Related]
7. Exploring the selectivity of inhibitor complexes with Bcl-2 and Bcl-XL: A molecular dynamics simulation approach.
Wakui N; Yoshino R; Yasuo N; Ohue M; Sekijima M
J Mol Graph Model; 2018 Jan; 79():166-174. PubMed ID: 29197725
[TBL] [Abstract][Full Text] [Related]
8. Towards the next generation of dual Bcl-2/Bcl-xL inhibitors.
Varnes JG; Gero T; Huang S; Diebold RB; Ogoe C; Grover PT; Su M; Mukherjee P; Saeh JC; MacIntyre T; Repik G; Dillman K; Byth K; Russell DJ; Ioannidis S
Bioorg Med Chem Lett; 2014 Jul; 24(14):3026-33. PubMed ID: 24881567
[TBL] [Abstract][Full Text] [Related]
9. Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy.
Leverson JD; Phillips DC; Mitten MJ; Boghaert ER; Diaz D; Tahir SK; Belmont LD; Nimmer P; Xiao Y; Ma XM; Lowes KN; Kovar P; Chen J; Jin S; Smith M; Xue J; Zhang H; Oleksijew A; Magoc TJ; Vaidya KS; Albert DH; Tarrant JM; La N; Wang L; Tao ZF; Wendt MD; Sampath D; Rosenberg SH; Tse C; Huang DC; Fairbrother WJ; Elmore SW; Souers AJ
Sci Transl Med; 2015 Mar; 7(279):279ra40. PubMed ID: 25787766
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and activity evaluation of broad-spectrum small-molecule inhibitors of anti-apoptotic Bcl-2 family proteins: characteristics of broad-spectrum protein binding and its effects on anti-tumor activity.
Zheng CH; Yang H; Zhang M; Lu SH; Shi D; Wang J; Chen XH; Ren XH; Liu J; Lv JG; Zhu J; Zhou YJ
Bioorg Med Chem Lett; 2012 Jan; 22(1):39-44. PubMed ID: 22172701
[TBL] [Abstract][Full Text] [Related]
11. Identification of Small Inhibitory Molecules Targeting the Bfl-1 Anti-Apoptotic Protein That Alleviates Resistance to ABT-737.
Mathieu AL; Sperandio O; Pottiez V; Balzarin S; Herlédan A; Elkaïm JO; Fogeron ML; Piveteau C; Dassonneville S; Deprez B; Villoutreix BO; Bonnefoy N; Leroux F
J Biomol Screen; 2014 Aug; 19(7):1035-46. PubMed ID: 24809353
[TBL] [Abstract][Full Text] [Related]
12. Celecoxib and Bcl-2: emerging possibilities for anticancer drug design.
Winfield LL; Payton-Stewart F
Future Med Chem; 2012 Mar; 4(3):361-83. PubMed ID: 22393942
[TBL] [Abstract][Full Text] [Related]
13. Probing Gallate-Mediated Selectivity and High-Affinity Binding of Epigallocatechin Gallate: a Way-Forward in the Design of Selective Inhibitors for Anti-apoptotic Bcl-2 Proteins.
Olotu FA; Agoni C; Adeniji E; Abdullahi M; Soliman ME
Appl Biochem Biotechnol; 2019 Mar; 187(3):1061-1080. PubMed ID: 30155742
[TBL] [Abstract][Full Text] [Related]
14. Pyrogallol-based molecules as potent inhibitors of the antiapoptotic Bcl-2 proteins.
Tang G; Yang CY; Nikolovska-Coleska Z; Guo J; Qiu S; Wang R; Gao W; Wang G; Stuckey J; Krajewski K; Jiang S; Roller PP; Wang S
J Med Chem; 2007 Apr; 50(8):1723-6. PubMed ID: 17378545
[TBL] [Abstract][Full Text] [Related]
15. Discovery of PROTAC BCL-X
Zhang X; Thummuri D; Liu X; Hu W; Zhang P; Khan S; Yuan Y; Zhou D; Zheng G
Eur J Med Chem; 2020 Apr; 192():112186. PubMed ID: 32145645
[TBL] [Abstract][Full Text] [Related]
16. Pyrazole and pyrimidine phenylacylsulfonamides as dual Bcl-2/Bcl-xL antagonists.
Schroeder GM; Wei D; Banfi P; Cai ZW; Lippy J; Menichincheri M; Modugno M; Naglich J; Penhallow B; Perez HL; Sack J; Schmidt RJ; Tebben A; Yan C; Zhang L; Galvani A; Lombardo LJ; Borzilleri RM
Bioorg Med Chem Lett; 2012 Jun; 22(12):3951-6. PubMed ID: 22608393
[TBL] [Abstract][Full Text] [Related]
17. Bcl-2 family proteins as targets for anticancer drug design.
Huang Z
Oncogene; 2000 Dec; 19(56):6627-31. PubMed ID: 11426648
[TBL] [Abstract][Full Text] [Related]
18. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.
Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T
J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis and pharmacological evaluation of new acyl sulfonamides as potent and selective Bcl-2 inhibitors.
Liu X; Zhang Y; Huang W; Tan W; Zhang A
Bioorg Med Chem; 2018 Jan; 26(2):443-454. PubMed ID: 29229225
[TBL] [Abstract][Full Text] [Related]
20. Enantiomeric trans β-aryl-δ-iodo-γ-lactones derived from 2,5-dimethylbenzaldehyde induce apoptosis in canine lymphoma cell lines by downregulation of anti-apoptotic Bcl-2 family members Bcl-xL and Bcl-2.
Pawlak A; Gładkowski W; Kutkowska J; Mazur M; Obmińska-Mrukowicz B; Rapak A
Bioorg Med Chem Lett; 2018 Apr; 28(7):1171-1177. PubMed ID: 29534928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
